Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04851392
Other study ID # 5929/005
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 11, 2019
Est. completion date June 16, 2021

Study information

Verified date September 2021
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date June 16, 2021
Est. primary completion date June 16, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 29 Years
Eligibility Inclusion Criteria: - Adolescents: Aged 16-17 - Adults: Aged 26-29 years - Self-reported cannabis use between 0.5 and 3 days/week, averaged over the last 3 months - Adults: Body mass index (BMI) between 18.5 and 29.9 - Adolescents: BMI between 2nd percentile and 98th percentile - Self-reported ability to consume approximately half a typical joint of cannabis by themselves within 20 minutes - Willing to be cannulated and have four blood samples taken at every acute session - Right-handed Exclusion Criteria: - Females: Pregnant or breast-feeding - Adults: Before the age of 18, had a period of 3 or more months when cannabis was used once per week or more frequently. - Severe cannabis use disorder (DSM-5) - Illicit drug use of any specific drug more than twice per month, averaged over the last 3 months - Receiving treatment (pharmacological or psychological) for a mental health problem within the last month - Lifetime psychosis - Lifetime psychosis of any immediate family member - Hypertension (systolic > 160 or diastolic > 100) - Dependent on tobacco or vaping nicotine (> 1 on the Heaviness of Smoking Index) - Currently taking a psychotropic medication that will likely affect dependent variables or interact with cannabis - Any physical or mental health condition, any medication, or any treatment, that the study doctor considers to be an exclusion - MRI contraindications - Significant asthma or respiratory problems - severity judged clinically - Self-reported moderate/severe acute unpleasant effects from cannabis which occur often or always - Positive alcohol breathalyser reading at any acute session (rearrange session) - Self-reported use of alcohol within 24 hours at any acute session (rearrange session) - Self-reported use of illicit drugs (including cannabis) within 72 hours at any acute session (rearrange session) - Positive saliva drug screen at any acute session (rearrange session)

Study Design


Intervention

Drug:
Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
Cannabis with THC without CBD
Cannabis with THC without CBD - inhaled and vaporised cannabis flower
Placebo cannabis
Placebo cannabis, without THC and without CBD - inhaled and vaporised

Locations

Country Name City State
United Kingdom University College London London

Sponsors (3)

Lead Sponsor Collaborator
University College, London Invicro, Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Psychotomimetic effect Measured by total Psychotomimetic States Inventory (PSI) score Measured once, 2 hours after the start of drug administration, on each drug condition
Primary Verbal episodic memory Measured by delayed prose recall performance Measured once, 2 hours after the start of drug administration, on each drug condition
Primary Strength of subjective drug effect Measured by self-reported 'feel drug effect', rated from 0 (not at all) to 10 (extremely) Measured 20 minutes after the start of drug administration, on each drug condition
Secondary Self-reported subjective effects Feel drug effect, like drug effect, dislike drug effect, alert, want to have cannabis, happy, relaxed, anxious, paranoid, mentally impaired, stoned, dry mouth, unmotivated, intensified sensory perception, want to listen to music, want food, want to see friends, rated from 0 (not at all) to 10 (extremely) Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Secondary Functional magnetic resonance imaging (fMRI) measured neural correlates Reward anticipation and reward feedback, response inhibition, spatial working memory, and resting-state Measured between 40 minutes and 1 hour & 20 minutes after the start of drug administration, on each drug condition
Secondary Magnetic resonance spectroscopy Measuring glutamate levels in the dorsal striatum Measured 1 hour & 30 minutes after the start of drug administration, on each drug condition
Secondary Positive and negative syndrome scale Kay et al. (1987). Higher scores reflect stronger positive and negative symptoms. Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition
Secondary Effort-related decision-making (i.e. amotivation) Measured by the physical effort task ('apple-gathering' task) as described in Husain & Roiser (2018) Measured 2 hours & 20 minutes after the start of drug administration, on each drug condition
Secondary Pleasure processing Measured by subjective liking in response to chocolate, music and cartoons, rated from 0 (not at all) to 10 (extremely), similar to Lawn et al. (2015) Measured 2 hours & 30 minutes after the start of drug administration, on each drug condition
Secondary Visual attentional bias to cannabis and food stimuli Measured by the visual dot-probe task, as described in Morgan et al. (2010) Measured 2 hours & 10 minutes after the start of drug administration, on each drug condition
Secondary Heart rate Measuring heart rate Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Secondary Blood pressure Measuring systolic and diastolic blood pressure. Measured -30 minutes, 20 minutes, 30 minutes, 2 hours, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Secondary Exogenous and endogenous cannabinoid levels in plasma Measuring THC and CBD and metabolites; and endocannabinoids Measured -30 minutes, 20 minutes, 30 minutes, and 2 hours & 40 minutes after the start of drug administration, on each drug condition
Secondary Dissociative states scale Bremner et al. (1998). Higher scores reflect greater dissociation. Measured 2 hours & 40 minutes after the start of drug administration, on each drug condition
See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity